ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 23 of 169 for:    breast,cancer,detection | Recruiting, Not yet recruiting, Available Studies

Contrast Enhanced Spectral Mammography vs. MRI for Breast Cancer Screening

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03482557
Recruitment Status : Recruiting
First Posted : March 29, 2018
Last Update Posted : June 18, 2018
Sponsor:
Collaborator:
GE Healthcare
Information provided by (Responsible Party):
Jordana Phillips, MD, Dana-Farber Cancer Institute

Brief Summary:
This research study is evaluating whether contrast enhanced mammography can be used as an alternative to breast Magnetic Resonance Imaging (MRI) for cancer screening

Condition or disease Intervention/treatment Phase
Breast Cancer Device: CESM Device: MRI Not Applicable

Detailed Description:

Mammography is the main way to help find breast cancers early so they can be treated. Unfortunately, mammography does not work as well in women who have dense breast tissue or who are at high-risk for breast cancer. In these women, breast MRI is also used to help find breast cancers.

Contrast enhanced mammography is a new type of mammogram. It uses contrast material combined with the mammogram to highlight areas that might be breast cancer and that could be missed on the mammogram alone. This is similar to breast MRI.

For this study, participants who are already getting a breast biopsy will have a contrast enhanced mammogram and a breast MRI before the biopsy. The participant's contrast enhanced mammogram and breast MRI images will then be included within a large collection of images. Radiologists will compare the images to see if the contrast enhanced mammograms and the breast MRI find the same number of breast cancers. If the investigators find they perform similarly, then contrast mammography may be used to aid in breast cancer screening in the future.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 96 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Screening
Official Title: Contrast Enhanced Spectral Mammography vs. MRI for Breast Cancer Screening
Actual Study Start Date : May 17, 2018
Estimated Primary Completion Date : April 30, 2021
Estimated Study Completion Date : April 30, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: CESM VS MRI

Each enrolled participant will receive both a CESM and MRI exam prior to the breast biopsy, if they had not been performed already as part of clinical care.

MRI: Breast MRI will be performed, if not already performed as part of clinical care.

CESM: After the MRI is complete, patients will be brought to the mammography department for the contrast enhanced mammogram. The CESM will only occur if not already performed as part of the patient's clinical care.

Biopsy: Patients will then have their biopsy. Any additional findings seen on the CESM or MRI will be worked up also.

Reader Study: The CESM and the MRI images will be included in a case set that is ready by 10 study radiologists at a later date, after the biopsy is performed. These radiologists will look at the images to see if CESM and MRI find the same number of breast cancers.

Device: CESM
Contrast enhanced mammography is a new type of mammogram. It uses contrast material combined with the mammogram to highlight areas that might be breast cancer and that could be missed on the mammogram alone
Other Name: Contrast Enhanced Spectral Mammography

Device: MRI
MRI uses magnets to create a detailed image of the tissues and bones inside of the body
Other Name: Magnetic Resonance Imaging




Primary Outcome Measures :
  1. Diagnostic accuracy of CESM compared with breast MRI for breast cancer screening [ Time Frame: 2 years ]
    We will determine whether CESM is non-inferior to breast MRI for breast cancer detection by comparing cancer detection rates on both studies using a multi-case multi-reader study model.


Secondary Outcome Measures :
  1. Diagnostic accuracy of CESM compared with abbreviated MRI for breast cancer detection [ Time Frame: 2 years ]
    We will determine whether CESM is non-inferior to abbreviated breast MRI for breast cancer detection by comparing cancer detection rates on both studies using a multi-case multi-reader study model.

  2. Diagnostic accuracy of CESM compared with conventional mammography for breast cancer screening [ Time Frame: 2 years ]
    We will determine whether CESM is superior to conventional 2D mammographic screening using a multi-case multi-reader study model.

  3. Patient preference for breast MRI versus CESM for breast cancer screening [ Time Frame: 2 years ]
    We will provide each patient with a survey following completing of the CESM and MRI exams to understand which exam the patients prefer for breast cancer screening



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   30 Years to 110 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Prospective Patient Recruitment

  • Women
  • Age > or equal to 30 years
  • Recommendation for breast biopsy has been made
  • Recommendation for biopsy will result from an imaging work-up originating with a screening exam (mammogram, tomosynthesis, ultrasound, or MRI) that was within 3 months of biopsy.

Reader Study Inclusion Criteria:

  • CESM and MRI exam performed within 3 months of one another.
  • CESM and breast MRI exams must be performed as part of imaging work-up based on a screening exam of any type (mammography, tomosynthesis, ultrasound, and MRI)
  • CESM studies will include at least four low energy and four recombined images (LCC, LMLO, RCC, RMLO).
  • MRI exams will include at least fluid sensitive sequence, multi-phase T1-weighted

Exclusion Criteria:

Prospective Patient Recruitment

  • Women with implants
  • Participants who have a known allergy to contrast media.
  • Participants who have a known severe allergic response to one or more allergens, defined as anaphylaxis
  • Participants with persistent asthma as defined by the National Heart, Lung, and Blood Institute.
  • Participants with Renal insufficiency or failure, as determined by GFR < 60 mL/min/1.73 m2 , performed per clinical protocol.
  • Participants who are pregnant. Pregnant women are excluded from this study due to the radiation dose from the CT scan and its potential teratogenic effects on the fetus.
  • Participants who are breastfeeding are excluded because there is an unknown but potential risk for adverse events in nursing infants secondary to contrast administration in the mother.
  • Participants with the following underlying medical conditions: multiple myeloma, myasthenia gravis, dysproteinemias, severe cardiac disease, aortic stenosis, primary pulmonary hypertension, cardiac arrythmia, or severe cardiomyopathy. These underlying medical conditions may make the participant more likely to develop a contrast reaction. This is based on the ACR contrast manual version 10.3 and hospital policy.
  • Participants with a concurrent active illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, thyroid storm.
  • Participants with thyroid carcinoma or thyroid disease for whom systemic radioactive iodine therapy is part of planned diagnostic work-up or treatment within 2 months following the contrast mammogram study.
  • Participants who are taking metformin at the time of the exam are excluded because of the challenge of monitoring these patients after iodinated contrast injection for the development of renal insufficiency and lactic acidosis

Reader Study Exclusion Criteria:

  • Imaging sets with implants.
  • Imaging sets in which a biopsy or surgical intervention was performed since the most recent screening exam, prior to acquisition of the study MRI or CESM.
  • Imaging sets in which a biopsy was recommended, but biopsy was not performed and 2 year imaging follow-up is not available

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03482557


Contacts
Contact: Layla Rahimi 617-667-3118 lrahimi@bidmc.harvard.edu

Locations
United States, Massachusetts
Beth Israel Deaconess Medical Center Recruiting
Boston, Massachusetts, United States, 02215
Contact: Layla Rahimi    617-667-3118    lrahimi@bidmc.harvard.edu   
Principal Investigator: Jordana Phillips, MD         
Sponsors and Collaborators
Dana-Farber Cancer Institute
GE Healthcare
Investigators
Principal Investigator: Jordana Phillips, MD Beth Israel Deaconess Medical Center

Responsible Party: Jordana Phillips, MD, Principal Investigator, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier: NCT03482557     History of Changes
Other Study ID Numbers: 17-689
First Posted: March 29, 2018    Key Record Dates
Last Update Posted: June 18, 2018
Last Verified: June 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: No
Pediatric Postmarket Surveillance of a Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by Jordana Phillips, MD, Dana-Farber Cancer Institute:
Breast Cancer
screening
breast MRI
contrast enhanced spectral mammography

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases